Literature review · Cognition & mood

Selank

An experimental peptide investigated in anxiety-related symptom studies and brain-connectivity experiments. The selected human evidence is preliminary and does not establish dependable clinical effectiveness or the performance of catalogue formulations.

By HeartPep · Reviewed · 4 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

Three small clinical reports and an acute imaging study provide preliminary human evidence. Clinical comparisons use other drugs or adjunct treatment rather than a clearly described, independently replicated placebo-controlled programme.

Identity & scope

This dossier covers the exact catalogue name Selank. A supplier name is not analytical confirmation of peptide sequence, composition or pharmaceutical equivalence.

Catalogue labels covered: Selank.

What the research shows

  • A 62-patient study reported similar anxiety-related effects for Selank and medazepam in its selected diagnostic groups.
  • A separate 52-person study examined Semax, Selank and placebo in different groups and reported connectivity differences. It did not test a Semax/Selank mixture.
  • Additional reports compare Selank with phenazepam or add Selank to phenazepam. Positive authors' conclusions require cautious reading because comparator and adjunct designs answer different questions.

Critical interpretation

Comparator and adjunct questions differ

The 2014 study compares one treatment with another; the 2015 study asks about adding Selank to phenazepam. Those results should not be combined into a general claim about Selank alone. In particular, a reported reduction in another drug's adverse effects is not evidence that Selank itself has no adverse effects or clinically important interactions. [3] [4]

Positive abstracts leave methodological uncertainty

These reports justify examining the full methods and seeking independent replication. Without a clearly documented placebo condition, masking and allocation procedure, improvement can reflect several influences besides a compound-specific effect. Diagnostic differences and different clinical scales also limit comparison across reports. Acute connectivity measurements address yet another question and cannot substitute for durable symptom outcomes. [3] [4] [2]

Limitations & uncertainties

  • The older clinical paper is Russian-language; this review verified its English abstract rather than the complete report.
  • A small active-comparator study cannot, by itself, establish equivalence to a treatment standard or exclude placebo and bias effects.
  • Acute imaging findings do not establish durable symptom relief. The papers do not validate any supplied vial or nasal formulation, manufacturing quality or longer-term safety.

Open research questions

  • Would larger, independently replicated placebo-controlled trials confirm meaningful symptom changes?
  • Are effects reproducible across populations and verified formulations, and how durable are they?

Selected papers & source records

Download bibliography
Human studyNamed compoundAbstract / record checked

1. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia (opens in a new tab)

Zozulia AA et al. (2008). Zh Nevrol Psikhiatr Im S S Korsakova. · PMID 18454096

Design & population
Clinical comparison of Selank and medazepam in 62 patients; PubMed indexes a randomized trial.
What the study found
The abstract reports similar anxiety-related effects between groups.
Limits on interpretation
Small active-comparator study; Russian full text not reviewed and no placebo arm described in the abstract.
Human studyNamed compoundAbstract / record checked

2. Functional Connectomic Approach to Studying Selank and Semax Effects (opens in a new tab)

Panikratova YR et al. (2020). Dokl Biol Sci. DOI: 10.1134/S001249662001007X (opens in a new tab) · PMID 32342318

Design & population
Acute resting-state fMRI study in 52 healthy participants receiving Semax, Selank or placebo separately.
What the study found
The authors reported amygdala-to-temporal-cortex connectivity differences.
Limits on interpretation
Surrogate imaging endpoints; neither clinical effectiveness nor combined-blend effects established.
Human studyNamed compoundAbstract / record checked

3. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders (opens in a new tab)

Medvedev VE et al. (2014). Zh Nevrol Psikhiatr Im S S Korsakova. · PMID 25176261

Design & population
Clinical comparison with phenazepam in 60 patients with anxiety-related or somatoform diagnoses.
What the study found
The abstract reports improved anxiety-related measures and quality of life with Selank.
Limits on interpretation
No placebo comparison or clear randomization/blinding description in the accessible abstract; Russian full methods were not reviewed.
Human studyNamed compoundAbstract / record checked

4. Optimization of the treatment of anxiety disorders with selank (opens in a new tab)

Medvedev VE et al. (2015). Zh Nevrol Psikhiatr Im S S Korsakova. DOI: 10.17116/jnevro20151156133-40 (opens in a new tab) · PMID 26356395

Design & population
Comparison of phenazepam alone in 30 patients with Selank plus phenazepam in 40 patients.
What the study found
The report describes earlier improvement and fewer reported phenazepam-associated adverse effects with adjunct Selank.
Limits on interpretation
An adjunct-treatment result does not establish Selank monotherapy. Allocation and blinding are not clear from the abstract.

Search & review scope

Targeted PubMed-domain searches and checks of original indexed study abstracts and citation metadata. Initial selection on 8 November was substantively extended on 9 November, with clinical searches, accessible full-text consultation and bounded publication-notice checks.. Checked 9 November 2026.

Selected human anxiety comparisons, adjunct-treatment evidence and healthy-participant brain-connectivity research.

Abstract-based narrative selection; Russian full reports were not reliably available. Some PubMed record pages returned incomplete content. No comprehensive correction/retraction or trial-registry audit is claimed.

Recorded search terms
  • site:pubmed.ncbi.nlm.nih.gov Selank 18454096
  • site:pubmed.ncbi.nlm.nih.gov/18454096/
  • site:pubmed.ncbi.nlm.nih.gov/32342318/
  • site:pubmed.ncbi.nlm.nih.gov "Selank" randomized anxiety placebo
  • site:pubmed.ncbi.nlm.nih.gov Selank clinical trial phenazepam anxiety
  • site:pubmed.ncbi.nlm.nih.gov/26356395/
  • site:pubmed.ncbi.nlm.nih.gov/26356395/ "Material" "Results"
  • "Optimization of the treatment of anxiety disorders with selank" full text

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. Selank: literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/selank.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes